Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2020 annual meeting of stockholders (the "Meeting") of Adamis Pharmaceuticals Corporation (the "Company") was reconvened on September 3, 2020, to consider and vote on (i) a proposal to approve an amendment to the Company's Restated Certificate of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 to 200,000,000, and (ii) a proposal to adopt and approve an amendment to the Company's Restated Certificate of Incorporation to effect a reverse stock split of the Company's outstanding shares of common stock, if the Company's Board of Directors in its discretion determines to effect a reverse stock split at any time before December 31, 2020, at a reverse stock split ratio ranging from 1-for-2 to 1-for-15, as determined by the Board of Directors at a later date.

At the reconvened Meeting, the stockholders voted on the following proposals, each of which is described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on July 10, 2020, as supplemented.

The final results for each of the matters considered at the reconvened Meeting were as follows:

1.

Approval of an amendment to the Company's Restated Certificate of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 to 200,000,000:



                     Votes For  Votes Against Votes Abstaining Broker Non-Votes
 Common Stock       38,597,707    18,875,371     1,126,693            -
 Series B Preferred 1,000,000         -              -                -

The proposal was approved.

2.

Approval of an amendment to the Company's Restated Certificate of Incorporation to effect a reverse stock split of the Company's outstanding shares of common stock, if the Company's Board of Directors in its discretion determines to effect a reverse stock split at any time before December 31, 2020, at a reverse stock split ratio ranging from 1-for-2 to 1-for-15, as determined by the Board of Directors at a later date:



                    Votes For  Votes Against Votes Abstaining Broker Non-Votes
Common Stock        32,833,457   24,990,669       775,645            -
Series B Preferred  1,000,000        -              -                -

The proposal was not approved.

© Edgar Online, source Glimpses